Executive Director, US Marketing, Rare Nephrology

Boston, MA (Hybrid)

$270K/yr – $405K/yrSenior Level10+ years expFull time

Posted 2 days ago

Job Summary

Land this role faster

Three separate AI actions to help you get more out of this role.

Stand Out

Get 3 specific ideas to make your application stronger for this role.

Resume Help

Get role-based resume tips tailored to this role.

Outreach Message

Generate a cold outreach message to someone on the hiring team.

Original Job Description

Alexion Pharmaceuticals, Inc. logo

Alexion Pharmaceuticals, Inc.

Glassdoor
3.9

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease. A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. GL/NP/0116GL/NP/0095 Community Guidelines: https://bit.ly/39x9gqy

Marketing team
240
Employees
5K
Headquarters
New Boston, Massachusetts, USA
Founded
1992

Employee Sentiment

Overall Rating
3.9 / 5
Recommend to a Friend
72%
CEO Approval
73%
Source: Glassdoor

Traffic Signals

Monthly Visitors
59.2K
Monthly Google Ads Budget
$0.0
Traffic Source Mix
Search
50.7%
Direct
34%
Referral
8.7%
Social
5.4%
Paid
1%

Headcount Trend

Current headcount: ~5K

Funding

Total Funding
$0.0
Last Raise
0 days ago
Last Raise Amount
$0.0
Last Round

Recent News

Morningstar, Inc.
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
Mar 18, 2025
GlobeNewswire News Room
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million by 2035 with Rising Demand for Orphan Drugs – Exclusive Report by Transparency Market Research, Inc.
Mar 18, 2025
PharmiWeb.com
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
Mar 17, 2025